1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

BJ Solomon, A Drilon, JJ Lin, L Bazhenova, K Goto, J De Langen, D-W Kim, J Wolf, C Springfeld, S Popat, DW-T Lim, CS Baik, A Hervieu, V Moreno Garcia, N Yang, S Thamake, F Ades, D Trone, B Besse